3.3. Safety
ADVERSE EVENTS
No serious AEs or serious ADRs were reported in either treatment group during the study period. The incidence of AEs in the CKD-495 75 mg and AAF 60 mg groups was 3.28% (4 of 122) and 4.17% (5 of 120), respectively. All ADRs were mild with no significant differences between the 2 treatment groups (Table Incidence of adverse events during the study (n, %).